Dose-response relations of azimilide in the management of symptomatic, recurrent, atrial fibrillation

We evaluated the efficacy and safety of azimilide, a new class III antiarrhythmic agent that blocks both the slow and fast components of the cardiac-delayed rectifier potassium currents in 4 randomized, double-blind, placebo-controlled trials with similar protocols. The purpose of this study was to...

Ausführliche Beschreibung